Abstract
Glucagon-like peptide-1 (GLP-1) has shown to influence the oxidative stress status in a number of in vitro, in vivo and clinical studies. Well-known effects of GLP-1 including better glycemic control, decreased food intake, increased insulin release and increased insulin sensitivity may indirectly contribute to this phenomenon, but glucose-independent effects on ROS level, production and antioxidant capacity have been suggested to also play a role. The potential ‘antioxidant’ activity of GLP-1 along with other proposed glucose-independent modes of action related to ameliorating redox imbalance remains a controversial topic but could hold a therapeutic potential against micro- and macrovascular diabetic complications. This review discusses the presently available knowledge from experimental and clinical studies on the effects of GLP-1 on oxidative stress in diabetes and diabetes-related complications.
Keywords: Glucagon-like peptide-1, oxidative stress, diabetes, diabetic complications.
Current Diabetes Reviews
Title:Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies
Volume: 12 Issue: 4
Author(s): Karen Ekkelund Petersen, Günaj Rakipovski, Kirsten Raun and Jens Lykkesfeldt
Affiliation:
Keywords: Glucagon-like peptide-1, oxidative stress, diabetes, diabetic complications.
Abstract: Glucagon-like peptide-1 (GLP-1) has shown to influence the oxidative stress status in a number of in vitro, in vivo and clinical studies. Well-known effects of GLP-1 including better glycemic control, decreased food intake, increased insulin release and increased insulin sensitivity may indirectly contribute to this phenomenon, but glucose-independent effects on ROS level, production and antioxidant capacity have been suggested to also play a role. The potential ‘antioxidant’ activity of GLP-1 along with other proposed glucose-independent modes of action related to ameliorating redox imbalance remains a controversial topic but could hold a therapeutic potential against micro- and macrovascular diabetic complications. This review discusses the presently available knowledge from experimental and clinical studies on the effects of GLP-1 on oxidative stress in diabetes and diabetes-related complications.
Export Options
About this article
Cite this article as:
Petersen Ekkelund Karen, Rakipovski Günaj, Raun Kirsten and Lykkesfeldt Jens, Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies, Current Diabetes Reviews 2016; 12 (4) . https://dx.doi.org/10.2174/1573399812666150918150608
DOI https://dx.doi.org/10.2174/1573399812666150918150608 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glycoxidation and Wound Healing in Diabetes: An Interesting Relationship
Current Diabetes Reviews Glycation of Human Serum Albumin in Diabetes: Impacts on the Structure and Function
Current Medicinal Chemistry Modulation of Nitric Oxide Pathway by Multiligands/RAGE Axis: A Crossing Point on the Road to Microvascular Complication in Diabetes
Current Enzyme Inhibition Connexins, Diabetes and the Metabolic Syndrome
Current Protein & Peptide Science miR-126 as a Therapeutic Agent for Diabetes Mellitus
Current Pharmaceutical Design Targeting Type 1 Diabetes Before and at the Clinical Onset of Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Skeletal Muscle in Motor Neuron Diseases: Therapeutic Target and Delivery Route for Potential Treatments
Current Drug Targets A Systematic Review on Pharmaceutical Diabetic Care Services in the United Arab Emirates (UAE)
Current Diabetes Reviews Immunological Approaches to Prevent Neuronal Apoptosis During Neuroinflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Circulatory Syndrome: An Evolution of the Metabolic Syndrome Concept!
Current Cardiology Reviews Extracellular Vesicles, Stem Cells and the Role of miRNAs in Neurodegeneration
Current Neuropharmacology Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility
Current Medicinal Chemistry Subject Index to Volume 4
Current Medicinal Chemistry - Central Nervous System Agents Gabapentin-Mediated Effects on Voltage- and Ligand-Gated Currents
Current Neuropharmacology Withanolides: Biologically Active Constituents in the Treatment of Alzheimer’s Disease
Medicinal Chemistry Intrinsically Disordered Domains, Amyloids and Protein Liquid Phases: Evolving Concepts and Open Questions
Protein & Peptide Letters Dimebon Attenuates the Aβ-Induced Mitochondrial Permeabilization
Current Alzheimer Research Editorial (Hot Topic: Organic Solute Transporters and Diseases: Potential Therapeutic Targets)
Current Molecular Pharmacology Position Based Nucleotide Analysis of miR168 Family in Higher Plants and its Targets in Mammalian Transcripts
MicroRNA Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders
Current Medicinal Chemistry